Animal Models Core Facility We are combining two previous cores dealing with mouse cancer nnodels into a single Animal IVIodeis Core that functions to help LCCC members with all aspects of mouse-related research. Core staff assists with animal handling, xenograft tumor models, colony management, therapeutic trials, imaging studies, allele phenotyping and the design and production of genetically engineered mice (GEM). This core adds value to the Cancer Center by enabling cost-efficient murine testing even by members who do not have significant infrastructure and expertise for animal work. The core is co-directed by Chariene Ross and Dale Cowley, with faculty co-advisors Norman Sharpless and Bernard Weissman. Dr. Sharpless and Dr. Cowley have been added to the leadership since the last cycle to add expertise in GEM models and expand core capabilities. Experimental help spans the spectrum from transgenic / knockout allele production and design to allele phenotyping, animal imaging and therapeutic testing of novel anti-cancer agents in xenograft and genetically engineered tumor models. The core has 39 users (97% use by peer reviewed members for Animal Studies). Significant growth has occurred in the animal studies component of the core during the last year with core staff operating beyond overall capacity since August 2009. We request an increased budget of $283,591 that will represent 15% of the total Animal Models Core budget to promote expanded use. The Animal Models Core will grow significantly during the next cycle, driven largely by increased NIH funding to UNC investigators, the 50% increase in campus animal space and a strategic plan featuring cancer genetics and preclinical therapeutics testing. The Genetic Medicine building has recently opened with space for over 40,000 additional cages. The Imaging Research Building will open in 2013 with 2,000 additional cages for longitudinal mouse therapy and Imaging protocols. The Animal Models Core is well positioned to become the nexus for Cancer Center members exploiting the power of GEMs and xenograft tumor models for basic and translational cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-37
Application #
8392168
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
37
Fiscal Year
2013
Total Cost
$281,540
Indirect Cost
$72,664
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications